Premium
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
Author(s) -
Jessen Frank,
Amariglio Rebecca E.,
Boxtel Martin,
Breteler Monique,
Ceccaldi Mathieu,
Chételat Gaël,
Dubois Bruno,
Dufouil Carole,
Ellis Kathryn A.,
Flier Wiesje M.,
Glodzik Lidia,
Harten Argonde C.,
Leon Mony J.,
McHugh Pauline,
Mielke Michelle M.,
Molinuevo Jose Luis,
Mosconi Lisa,
Osorio Ricardo S.,
Perrotin Audrey,
Petersen Ronald C.,
Rabin Laura A.,
Rami Lorena,
Reisberg Barry,
Rentz Dorene M.,
Sachdev Perminder S.,
Sayette Vincent,
Saykin Andrew J.,
Scheltens Philip,
Shulman Melanie B.,
Slavin Melissa J.,
Sperling Reisa A.,
Stewart Robert,
Uspenskaya Olga,
Vellas Bruno,
Visser Pieter Jelle,
Wagner Michael
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.01.001
Subject(s) - comparability , cognitive decline , disease , terminology , cognition , dementia , medicine , cognitive impairment , set (abstract data type) , psychology , clinical psychology , psychiatry , pathology , computer science , linguistics , philosophy , mathematics , combinatorics , programming language
There is increasing evidence that subjective cognitive decline (SCD) in individuals with unimpaired performance on cognitive tests may represent the first symptomatic manifestation of Alzheimer's disease (AD). The research on SCD in early AD, however, is limited by the absence of common standards. The working group of the Subjective Cognitive Decline Initiative (SCD‐I) addressed this deficiency by reaching consensus on terminology and on a conceptual framework for research on SCD in AD. In this publication, research criteria for SCD in pre‐mild cognitive impairment (MCI) are presented. In addition, a list of core features proposed for reporting in SCD studies is provided, which will enable comparability of research across different settings. Finally, a set of features is presented, which in accordance with current knowledge, increases the likelihood of the presence of preclinical AD in individuals with SCD. This list is referred to as SCD plus .